CRL Charles River Laboratories

$167.57

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Charles River Laboratories

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Website: https://www.criver.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1100682
Address
251 BALLARDVALE ST, WILMINGTON, MA, US
Valuation
Market Cap
$5.21B
P/E Ratio
530.25
PEG Ratio
3.40
Price to Book
1.50
Performance
EPS
$0.20
Dividend Yield
—
Profit Margin
0.55%
ROE
0.71%
Technicals
50D MA
$153.54
200D MA
$185.39
52W High
$254.15
52W Low
$91.86
Fundamentals
Shares Outstanding
49M
Target Price
$159.11
Beta
1.45

CRL EPS Estimates vs Actual

● Estimated
● Actual

CRL News & Sentiment

Nov 17, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Charles River ( CRL ) International Revenue Performance Explored
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Nov 10, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS ...
Nov 10, 2025 • Benzinga SOMEWHAT-BULLISH
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics - Dyadic International ( NASDAQ:DYAI )
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- ERS Genomics Limited ( 'ERS' ) , the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today ...
Nov 06, 2025 • Benzinga SOMEWHAT-BULLISH
This Charles River Laboratories Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Jack Henry & Associates ( NASDAQ:JKHY ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Nov 06, 2025 • Benzinga SOMEWHAT-BULLISH
Robinhood To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday - Bentley Systems ( NASDAQ:BSY ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised Kratos Defense & Security Solutions, Inc. ( NASDAQ:KTOS ) price target from $80 to $95.
Nov 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Charles River ( CRL ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 9:00 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Sentiment Snapshot

Average Sentiment Score:

0.139
50 articles with scored sentiment

Overall Sentiment:

Neutral

CRL Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.57 Surprise
  • Reported EPS: $3.12
  • Estimate: $2.55
  • Whisper: —
  • Surprise %: 22.4%
May 07, 2025
Mar 31, 2025 (Pre market)
0.27 Surprise
  • Reported EPS: $2.34
  • Estimate: $2.07
  • Whisper: —
  • Surprise %: 13.0%
Feb 19, 2025
Dec 31, 2024 (Pre market)
0.13 Surprise
  • Reported EPS: $2.66
  • Estimate: $2.53
  • Whisper: —
  • Surprise %: 5.1%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.17 Surprise
  • Reported EPS: $2.59
  • Estimate: $2.42
  • Whisper: —
  • Surprise %: 7.0%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.41 Surprise
  • Reported EPS: $2.80
  • Estimate: $2.39
  • Whisper: —
  • Surprise %: 17.1%
May 09, 2024
Mar 31, 2024 (Pre market)
0.2 Surprise
  • Reported EPS: $2.27
  • Estimate: $2.07
  • Whisper: —
  • Surprise %: 9.7%
Feb 14, 2024
Dec 31, 2023 (Pre market)
0.06 Surprise
  • Reported EPS: $2.46
  • Estimate: $2.40
  • Whisper: —
  • Surprise %: 2.5%
Nov 08, 2023
Sep 30, 2023 (Pre market)
0.35 Surprise
  • Reported EPS: $2.72
  • Estimate: $2.37
  • Whisper: —
  • Surprise %: 14.8%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $2.69
  • Estimate: $2.64
  • Whisper: —
  • Surprise %: 1.9%

Financials